Study S001639

Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03233178
Acronym: ALT
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 4000
Start: 2017-01
Primary completion: 2017-06
Lead sponsor: LMC Diabetes & Endocrinology Ltd.
Conditions: T2DM (Type 2 Diabetes Mellitus); Fatty Liver; NAFLD
Interventions: OTHER:Non-interventional
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control [1 year]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026949	SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Bajaj HS, Diabetes & metabolism	2018	Nonrandomized study	PMID 30149145 DOI	cites ClinicalTrials.gov:NCT03233178; registry reference DERIVED:30149145